Search

The article discusses the need for practitioners to view inter partes review (IPR) cases in three parts, involving the institution decision, to better serve their clients. Topics covered include the impact of the America Invents Act on awareness about patents and the release of monthly statistics of IPT cases by the U.S. Patent and Trademark Office. Also mentioned is the involvement of the agency until the final oral hearing of the cases.

The article discusses the importance of Section 101 to modern patent litigation, focusing on its application by district courts on Section 101 motions since the U.S. Supreme Court's Alice decision. It mentions the increasing number of decision on Section 101 motions with significant success rates, with particular consideration on the importance of venue in the viability of a patent-eligibility challenge.

The article explores several practical considerations when defining and identifying what is patentable subject matter and an unpatentable abstract idea. Several cases that address the patentability of software inventions, including the U.S. Federal Circuit's CLS Bank v. Alice Corp., are discussed. The need to consider the implications of the various approaches to the prosecution and litigation of cases related to software patents is also emphasized.

The article assesses whether the early post-grant decisions of the Patent Trial and Appeal Board (PTAB) favor intellectual property rights petitioners. Topics covered include the high number of cases faced by the board in relation to post-grant patent review mechanisms. Also mentioned are the requirements for driving patent claims in inter partes review such as having broader claim construction and easy-to-cancel claims.

The article discusses the efficacy of two available options for a patent trial proceedings before the U.S. Patent Trial and Appeal Board (PTAB) court. The two options mentioned are inter partes review (IPR) and post-grant review (PGR). It mentions PGR being more powerful as it has a wider scope for any requirement of patentability. It cites a case in the PTAB, Mylan Pharmaceuticals Inc. v. Yeda Research & Development Co. Ltd. to further illustrate the issue.

The article focuses on the patent litigation in the U.S. and new cases that help defend patentability challenges under section 101. Topics discussed include patent-ineligible abstract idea into a patent-eligible invention, patents challenged under patent infringement act, patent claim under the act and end of certain classes of computer and software-based patents.